BioVie Says Last On-Treatment Visit Completed In Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID; Expects Topline Results Before End Of September 2026
Share
Why It Matters
BioVie finished giving medicine to patients in a test for a long COVID treatment called bezisterim, and they'll share what they learned by the end of next September. When a company finishes testing and announces results soon, watch to see if the medicine actually helped people feel better.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.